Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Mbx Biosciences Inc (MBX)

Mbx Biosciences Inc (MBX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,418,173
  • Shares Outstanding, K 47,510
  • Annual Sales, $ 0 K
  • Annual Income, $ -86,970 K
  • EBIT $ -98 M
  • EBITDA $ -98 M
  • 60-Month Beta 1.06
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.28

Options Overview Details

View History
  • Implied Volatility 105.06% (unch)
  • Historical Volatility 73.88%
  • IV Percentile 36%
  • IV Rank 11.83%
  • IV High 309.05% on 07/18/25
  • IV Low 77.70% on 10/24/25
  • Expected Move (DTE 15) 7.91 (24.51%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 10
  • Volume Avg (30-Day) 60
  • Put/Call OI Ratio 0.32
  • Today's Open Interest 2,383
  • Open Int (30-Day) 2,933
  • Expected Range 24.38 to 40.20

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.61
  • Number of Estimates 3
  • High Estimate $-0.55
  • Low Estimate $-0.68
  • Prior Year $-0.71
  • Growth Rate Est. (year over year) +14.08%

Price Performance

See More
Period Period Low Period High Performance
1-Month
26.14 +23.53%
on 03/30/26
33.47 -3.51%
on 03/02/26
-0.26 (-0.80%)
since 02/27/26
3-Month
26.14 +23.53%
on 03/30/26
44.89 -28.07%
on 01/15/26
+0.75 (+2.38%)
since 12/31/25
52-Week
4.81 +571.74%
on 04/07/25
44.89 -28.07%
on 01/15/26
+25.43 (+370.70%)
since 04/01/25

Most Recent Stories

More News
MBX Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Highlights

Phase 3 trial of once-weekly canvuparatide remains on track to initiate in Q3 2026 following recently completed, successful End-of-Phase 2 meeting with FDA 12-week MAD Phase 1 data from MBX 4291...

MBX : 32.29 (+8.17%)
MBX Biosciences Appoints Karen Basbaum as Chief Business Officer

CARMEL, Ind., March 10, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision...

MBX : 32.29 (+8.17%)
CORRECTING & REPLACING -- MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism

In the fourth paragraph, we are replacing  milligrams with micrograms . The corrected press release follows. CARMEL, Ind., March 09, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX),...

MBX : 32.29 (+8.17%)
MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism

CARMEL, Ind., March 09, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision...

MBX : 32.29 (+8.17%)
MBX Biosciences to Participate in Upcoming March Investor Conferences

CARMEL, Ind., Feb. 23, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel precision...

MBX : 32.29 (+8.17%)
MBX Biosciences to Participate in Upcoming Investor Conferences

CARMEL, Ind., Feb. 11, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel precision...

MBX : 32.29 (+8.17%)
MBX Biosciences Appoints Laurie Stelzer to Board of Directors as Audit Committee Chair

CARMEL, Ind., Jan. 22, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision...

MBX : 32.29 (+8.17%)
MBX Biosciences to Provide 2026 Outlook and Business Update at 44th Annual J.P. Morgan Healthcare Conference

One-year follow-up data from Phase 2 trial of once-weekly canvuparatide, a potential best-in-class therapy for hypoparathyroidism, anticipated in Q2 2026; Phase 3 initiation on track for Q3 2026 12-week...

MBX : 32.29 (+8.17%)
MBX Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13

CARMEL, Ind., Dec. 15, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies...

MBX : 32.29 (+8.17%)
MBX Biosciences to Participate in the 37th Annual Piper Sandler Healthcare Conference

CARMEL, Ind., Nov. 18, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies...

MBX : 32.29 (+8.17%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed above 50%. The market is indicating support for a bullish trend.

See More Share

Business Summary

MBX Biosciences Inc. is a clinical-stage biopharmaceutical company. It focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company's pipeline includes its lead product candidate MBX 2109, MBX 1416 and MBX 4291. MBX...

See More

Key Turning Points

3rd Resistance Point 36.14
2nd Resistance Point 34.57
1st Resistance Point 33.43
Last Price 32.29
1st Support Level 30.72
2nd Support Level 29.15
3rd Support Level 28.01

See More

52-Week High 44.89
Last Price 32.29
Fibonacci 61.8% 29.58
Fibonacci 50% 24.85
Fibonacci 38.2% 20.12
52-Week Low 4.81

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.